placeholder newsslider


ARVO2020 cancelled because of Coronavirus (COVID-19)

ARVO has decided to cancel the Annual Meeting to have taken place May 1 – 7 in Baltimore, Md, USA

New Technologies for Outcome Measures in Uveal Melanoma

Basel Series of Special Interest Focus Groups (SIFG) - „New Technologies for Outcome Measures in Uveal Melanoma” In Collaboration with the European Ocular Oncology Group and the International Society of Ocular Oncology

Eye care is key when you're working from home

If you're one of the many people who've switched to working at home during the COVID-19 pandemic, you need to take care of your eyes, the American Academy of Ophthalmology says.

Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy

Ocuphire Pharma announced that it has screened the first patient in ZETA-1, a phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR). Effects on diabetic macular edema will be explored as a secondary outcome. A number of retinal centers across the US are active and recruiting eligible diabetic retinopathy patients.

Biden wants $6.5 billion for new health agency to speed treatments

The Biden administration began to flesh out a proposal for a new agency—modeled on the military’s Defense Advanced Research Projects Agency (DARPA)—that would seek to speed the development of medical treatments by funding risky, innovative projects. The agency, dubbed ARPA-Health (ARPA-H), would be housed at the National Institutes of Health and have a 2022 budget of $6.5 billion.

Santen Announces Global Research Initiative to Study and Develop New Treatments for Glaucoma

Santen announced a research initiative with scientists from Massachusetts Eye and Ear, and Ulster University, UK, to research and develop novel treatments for glaucoma.

UK announces €250M towards Horizon Europe participation cost following scientist revolt

Government comes up with 11th hour funds to help meet association cost after lobbying effort by science leaders. But critics still call plan ‘very opaque’, and say it isn’t enough

Alcon Canada Introduces UV Only IOLs for AcrySof IQ PanOptix and AcrySof IQ Vivity Portfolios

Alcon has announced the availability of AcrySof IQ PanOptix UV IOL, AcrySof IQ PanOptix Toric UV IOL, AcrySof IQ Vivity UV IOL, and AcrySof IQ Vivity Toric UV IOL as part of the presbyopia-correcting lens portfolio in Canada.

European Innovation Council opens €1B funding round for start-ups

Small and medium-sized companies can apply for grants of up to €2.5M and direct equity investments of up to €15M in the first calls

Biden pursues giant boost for science spending

US president’s first budget proposal emphasizes applied research and public health, and aims to tackle climate change and racial injustice.

Essilor to Present New Results for its Stellest Lens for Children With Myopia

Essilor will unveil pivotal 2-year clinical trial results of its Stellest lens for myopia. The 2-year results demonstrate that Essilor Stellest lenses slow down myopia progression by 67% on average, when compared to single vision lenses, when worn at least 12 hours a day, according to Essilor.

‘We must adapt’: EU research chief on Europe’s €100-billion funding programme

Commissioner Mariya Gabriel will oversee the implementation of the Horizon Europe scheme.

Publication of Preclinical Efficacy Results on IOP-Lowering Compounds announced

Nicox SA anounces the publication of Preclinical Efficacy Results on a new class of Non-PGA NO-Donating IOP-Lowering Compounds

Bausch + Lomb Launches Alaway Preservative Free Antihistamine Eye Drops

Bausch + Lomb announced the US launch of Alaway Preservative Free (ketotifen fumarate ophthalmic solution 0.035%) antihistamine eye drops. Bausch + Lomb says Alaway is the first and only over-the-counter (OTC) preservative-free antihistamine eye itch relief drop approved by the FDA.

Treating vision loss globally would have social and economic benefits

Written by 73 leading experts from 25 countries, The Lancet Global Health Commission Report on Global Eye Health reveals that with the right tools, strategies, and sufficient funding, improving eye health can have immediate and substantial benefits for the economic and social prosperity of individuals and nations.